EGFR and non-small cell lung carcinoma: In a small study including 41 NSCLC patients, it was demonstrated that patients with mutated plasma exoNA (KRAS, EGFR, BRAF) and low MAF had longer median PFS and time-to-treatment failure, suggesting that the molecular profiling of plasma exoNA can be predictive of clinical outcomes [177].